Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ

Abstract

ObjectiveTo evaluate the expression of survivin protein in low- and high-grade ductal carcinoma in situ.MethodsBreast tissue fragments obtained by incisional biopsy and surgical procedures of 37 women with ductal carcinoma in situ of the breast were subdivided into two groups: Group A, composed of women with low-grade ductal carcinoma in situ, and Group B, women with high-grade ductal carcinoma in situ. Survivin protein expression test was performed by immunohistochemistry, using a monoclonal antibody clone I2C4. The criterion to evaluate survivin immunoexpression was based on the percentage of neoplastic cells that presented brown-gold staining. This criterion was positive when the percentage of stained cells was ≥10%.ResultsThe survivin protein was expressed in 22 out of 24 cases of high-grade ductal carcinoma in situ (78%), whereas, in Group A, of low-grade ductal carcinoma in situ (n=13), it was positive in only 6 cases (21.40%; p=0.004).ConclusionThe frequency of expression of survivin was significantly higher in the group of patients with high-grade ductal carcinoma in situ compared to those in the low-grade ductal carcinoma in situ group.

Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts

“…It was highlighted as a promising prognostic biomarker and a potential oncological drug target. Recent bioinformatics evaluations conducted in independent datasets support the key role of survivin in BC [ 12 , 13 ]. However, the clinical significance as well as the molecular mechanisms behind BIRC5/survivin involvement in BC development remains unclear.…”

Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat

“…Okumura et al [35] observed the cytoplasmic activity of survivin in 55.8% (29/52) of cases. Equally, Chade et al [36] reported survivin expression in up to 75.6% (28/37) of in situ cancers. However, they observed a significant difference when comparing the grade of histopathology.…”

BIRC5 (baculoviral IAP repeat containing 5)

“…BIRC5 protein expression was found in 78% of highgrade and 21.4% of low-grade patients with ductal carcinoma in situ, indicating that BIRC5 expression is associated with an advanced stage phenotype in breast cancer (Chade et al, 2018). In addition, increased Estrogen positive breast cancer subtypes have been connected to increased BIRC5 regulation, w levels of BIRC5 mRNA (2.24 fold) were observed in whole blood samples from breast cancer patients when compared to healthy donors .…”